1998
DOI: 10.1677/erc.0.0050325
|View full text |Cite
|
Sign up to set email alerts
|

Maximal androgen withdrawal for prostate cancer therapy: current status and future potential

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2000
2000
2013
2013

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(9 citation statements)
references
References 119 publications
0
9
0
Order By: Relevance
“…Importantly, however, PRK1 signalling strongly induces AR activity in the presence of the adrenal androgens (Figure 6A). We then tested the anti‐androgen CPA, which is commonly used during androgen ablation therapy to block the effects of androgens (Leewansangtong and Crawford, 1998). As expected, CPA at 10 −5 M only marginally activates the AR (Figure 6B).…”
Section: Resultsmentioning
confidence: 99%
“…Importantly, however, PRK1 signalling strongly induces AR activity in the presence of the adrenal androgens (Figure 6A). We then tested the anti‐androgen CPA, which is commonly used during androgen ablation therapy to block the effects of androgens (Leewansangtong and Crawford, 1998). As expected, CPA at 10 −5 M only marginally activates the AR (Figure 6B).…”
Section: Resultsmentioning
confidence: 99%
“…Localized disease can be treated relatively successfully by radical prostatectomy (Catalona and Smith, 1998). In contrast, treatments for metastatic prostate cancer, including androgen ablation, are initially effective, but the majority of patients relapse with androgen independent prostate cancer (Denis, 1998;Leewansangtong and Crawford, 1998). The incidence of prostate cancer and the lack of good, long-term treatments for metastatic disease highlight the need for new chemopreventive and chemotherapeutic treatments.…”
Section: Prostate Cancermentioning
confidence: 99%
“…Androgens-Androgen ablation is often used in the treatment of metastatic prostate cancer; however, patients generally relapse with androgen independent disease (Denis, 1998;Leewansangtong and Crawford, 1998). Because of the importance of androgens in prostate cancer, it is important to elucidate any interactions between androgens and 1,25(OH) 2 D 3 in prostate cancer cells.…”
Section: Role Of Androgens and Growth Factors In 125(oh) 2 D 3 Actionmentioning
confidence: 99%
“…The tumor of the prostate is, actually, the most frequent malignancy and the second leading cause of male cancer deaths in the Western countries [1,2]. Prostate cancer is usually androgen-dependent in its early stages [3], when most patients positively respond to the suppression of testosterone secretion and/or action, which is mainly achieved through agonistic analogs of LHRH and antiandrogens, given either alone or in combination [3,4]. In later stages, after a given time of tumor remission, a new phase of growth appears in which surviving cancer cells have lost their androgen dependence.…”
Section: Introductionmentioning
confidence: 99%